The present study aimed to evaluate the cost-effectiveness of CDK4/6 inhibitors in combination with letrozole as a first-line treatment for hormonal receptor-positive and HER-2-negative advanced breast cancer in addition to evaluating their cost-effectiveness versus one another. The gene discussed is ERBB2; the disease is breast cancer.